Evolution of the Average Target: AstraZeneca PLC

Evolution of the Target Price: AstraZeneca PLC

Changes in Analyst Recommendations: AstraZeneca PLC

704792b5a6518.rLHxuMwOWzas3GxZIRnX3VDVpamnP_Odsq1hyV6JTG8.5MmzjIFeLVvCsAEyUjThqx2S78DzWLXo4YBQqza9HV-c94vArkkUWMCSXA~20daefe9a5b1303065454d3192c26278
02:40am AstraZeneca PLC : Buy rating from Jefferies ZD
02:25am AstraZeneca PLC : JP Morgan keeps its Buy rating ZD
01:00am AlphaValue/Baader Europe Notes GSK's Plans to Address Upcoming Patent Cliff; Price Target Down MT
Sep. 15 Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says MT
Sep. 15 Deutsche Bank Upgrades AstraZeneca to Hold, Lifts PT MT
Sep. 15 Berenberg Trims Price Target on AstraZeneca to $203 From $214, Keeps Buy Rating MT
Sep. 15 Berenberg Maintains AstraZeneca at Buy as Pipeline Success Offsets Recent Setbacks; Price Target Down MT
Sep. 15 Berenberg likes GSK; Deutsche Bank lifts Astra AN
Sep. 15 AstraZeneca PLC : Berenberg keeps its Buy rating ZD
Sep. 15 AstraZeneca PLC : Deutsche Bank withdraws its Sell rating ZD
Sep. 14 AstraZeneca PLC : JP Morgan reiterates its Buy rating ZD
Sep. 14 AstraZeneca PLC : Jefferies reiterates its Buy rating ZD
Sep. 10 Berenberg Notes AstraZeneca's 'Stellar' Tozorakimab Late-stage Data; Buy Retained MT
Sep. 10 AstraZeneca PLC : Gets a Sell rating from Deutsche Bank ZD
Sep. 10 AstraZeneca PLC : Berenberg reiterates its Buy rating ZD
Sep. 09 RBC Capital Markets Initiates AstraZeneca Coverage at Outperform MT
Sep. 09 RBC Initiates AstraZeneca at Outperform With GBP145 Price Target MT
Sep. 09 RBC prefers Astra to GSK; HSBC cuts Burberry AN
Sep. 09 RBC Initiates AstraZeneca at Outperform as Near-term Overhangs Create 'Attractive' Entry Point MT
Sep. 08 AstraZeneca PLC : Gets a Buy rating from RBC ZD
Sep. 08 AstraZeneca PLC : Buy rating from JP Morgan ZD
Sep. 08 AstraZeneca PLC : Receives a Sell rating from Deutsche Bank ZD
Sep. 08 Jefferies raises Autotrader and Rightmove AN
Sep. 08 AstraZeneca PLC : Barclays maintains a Buy rating ZD
Sep. 07 BofA Upbeat on AstraZeneca's Camizestrant After US Approval Based on Serena-6 Trial Results MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+16.61%
+4.01%
+5.92%
+3.88%
+10.12%
+29.67%
+3.3%
+12.42%
+8.1%
Average +10.45%
Weighted average by Cap. +10.72%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
163.39USD
Average target price
211.86USD
Spread / Average Target
+29.67%
High Price Target
273.17USD
Spread / Highest target
+67.19%
Low Price Target
151.95USD
Spread / Lowest Target
-7.00%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!